NO20015156D0 - 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse - Google Patents

5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse

Info

Publication number
NO20015156D0
NO20015156D0 NO20015156A NO20015156A NO20015156D0 NO 20015156 D0 NO20015156 D0 NO 20015156D0 NO 20015156 A NO20015156 A NO 20015156A NO 20015156 A NO20015156 A NO 20015156A NO 20015156 D0 NO20015156 D0 NO 20015156D0
Authority
NO
Norway
Prior art keywords
pyridyl
production
same
azole compounds
azole
Prior art date
Application number
NO20015156A
Other languages
English (en)
Other versions
NO320588B1 (no
NO20015156L (no
Inventor
Shigenori Ohkawa
Seiji Miwatashi
Naoyuki Kanzaki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20015156D0 publication Critical patent/NO20015156D0/no
Publication of NO20015156L publication Critical patent/NO20015156L/no
Publication of NO320588B1 publication Critical patent/NO320588B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
NO20015156A 1999-04-23 2001-10-22 5-pyridyl-1,3-azolforbindelser, fremgangsmate for fremstilling av disse, farmasoytisk preparat omfattende disse og anvendelse av disse. NO320588B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11668699 1999-04-23
JP22465099 1999-08-06
PCT/JP2000/002575 WO2000064894A1 (fr) 1999-04-23 2000-04-20 Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation

Publications (3)

Publication Number Publication Date
NO20015156D0 true NO20015156D0 (no) 2001-10-22
NO20015156L NO20015156L (no) 2001-12-18
NO320588B1 NO320588B1 (no) 2005-12-27

Family

ID=26454974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015156A NO320588B1 (no) 1999-04-23 2001-10-22 5-pyridyl-1,3-azolforbindelser, fremgangsmate for fremstilling av disse, farmasoytisk preparat omfattende disse og anvendelse av disse.

Country Status (24)

Country Link
US (3) US7101899B1 (no)
EP (1) EP1180518B1 (no)
KR (2) KR100558123B1 (no)
CN (1) CN1156471C (no)
AU (1) AU765473B2 (no)
BR (1) BR0009952A (no)
CA (1) CA2370264A1 (no)
CZ (1) CZ300709B6 (no)
DE (1) DE60033028T2 (no)
DK (1) DK1180518T3 (no)
ES (1) ES2275500T3 (no)
HK (1) HK1044338B (no)
HU (1) HUP0203766A3 (no)
IL (1) IL146105A (no)
MX (1) MXPA01010675A (no)
MY (1) MY126736A (no)
NO (1) NO320588B1 (no)
NZ (1) NZ515215A (no)
PL (1) PL351148A1 (no)
PT (1) PT1180518E (no)
RU (1) RU2237062C2 (no)
SI (1) SI1180518T1 (no)
SK (1) SK286666B6 (no)
WO (1) WO2000064894A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064894A1 (fr) * 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US7067537B2 (en) 2000-12-08 2006-06-27 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
EP1721609A3 (en) * 2001-05-16 2007-01-31 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
JP4409935B2 (ja) * 2001-05-31 2010-02-03 サノフィ−アベンティス アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンａ３リガンドとしての使用
CA2450400A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
MXPA04003729A (es) * 2001-10-22 2004-07-23 Tanabe Seiyaku Co Compuestos de 4-imidazolin-2-ona.
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
AU2003246927A1 (en) * 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
US7157473B2 (en) 2002-08-23 2007-01-02 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing HCV infection
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
DK1700856T3 (en) * 2003-12-26 2015-12-14 Kyowa Hakko Kirin Co Ltd thiazole
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
JP2007223903A (ja) * 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
EP1810972B1 (en) * 2004-11-10 2012-01-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
EP1883633A2 (en) 2005-05-02 2008-02-06 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
KR100848205B1 (ko) * 2005-06-20 2008-07-24 주식회사 동부하이텍 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물
US7494519B2 (en) * 2005-07-28 2009-02-24 3M Innovative Properties Company Abrasive agglomerate polishing method
WO2007015528A1 (ja) 2005-08-02 2007-02-08 Kyowa Hakko Kogyo Co., Ltd. 睡眠障害の治療および／または予防剤
US20090005568A1 (en) * 2005-08-18 2009-01-01 Pharmacopeia Drug Discovery, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
AU2006298132A1 (en) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
BRPI0617948A2 (pt) 2005-10-28 2011-08-09 Takeda Pharmaceutical composto, pró-droga de um composto, agente farmacêutico, método para inibir uma metaloproteinase de matriz, e, uso de um composto
US20100227804A1 (en) * 2006-01-18 2010-09-09 The University Of Tokyo Gel-forming composition for medical use, administration device for the composition, and drug release controlling carrier
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
WO2008023462A1 (fr) 2006-08-21 2008-02-28 Next21 K.K. Moulage d'os, charge d'os et procédé de production d'une charge d'os
JP4588791B2 (ja) 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物
CN101657216B (zh) 2007-04-20 2012-11-21 大同化成工业株式会社 干式固体分散体用基剂、含有该基剂的固体分散体及含有该分散体的组合物
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
EP2540286A4 (en) 2010-02-26 2015-05-27 Nisshin Kasei Co Ltd HARD CAPSULE AND METHOD OF PRODUCING THE SAME
EP2902014B1 (en) 2012-09-26 2019-03-06 Takeda Pharmaceutical Company Limited Process for producing solid particles
CN103288817A (zh) * 2013-07-02 2013-09-11 天津理工大学 一种基于1,3,4-噻二唑和1,3,4-噁二唑的希夫碱衍生物及其制备方法和应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
KR101851972B1 (ko) 2015-10-21 2018-06-11 주식회사 제이아이바이오팜 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물 및 그 제조방법
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
AU2018346709A1 (en) 2017-10-05 2020-04-16 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JPH0570446A (ja) 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
WO1997012876A1 (en) 1995-10-06 1997-04-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5684439A (en) * 1995-10-10 1997-11-04 Motorola, Inc. Half wave ceramic filter with open circuit at both ends
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物
WO2000064894A1 (fr) * 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
CA2450400A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions

Also Published As

Publication number Publication date
US7276527B2 (en) 2007-10-02
CZ300709B6 (cs) 2009-07-22
CN1156471C (zh) 2004-07-07
AU765473B2 (en) 2003-09-18
RU2237062C2 (ru) 2004-09-27
IL146105A0 (en) 2002-07-25
KR100449215B1 (ko) 2004-09-18
US20090048307A1 (en) 2009-02-19
HK1044338B (en) 2007-06-29
MY126736A (en) 2006-10-31
CZ20013805A3 (cs) 2002-04-17
EP1180518A4 (en) 2004-09-15
EP1180518A1 (en) 2002-02-20
BR0009952A (pt) 2002-03-26
CA2370264A1 (en) 2000-11-02
AU3840100A (en) 2000-11-10
IL146105A (en) 2005-09-25
DE60033028D1 (de) 2007-03-08
US7101899B1 (en) 2006-09-05
NO320588B1 (no) 2005-12-27
ES2275500T3 (es) 2007-06-16
WO2000064894A1 (fr) 2000-11-02
DE60033028T2 (de) 2007-11-15
KR100558123B1 (ko) 2006-03-07
KR20020059453A (ko) 2002-07-12
CN1353710A (zh) 2002-06-12
HK1044338A1 (en) 2002-10-18
KR20010111314A (ko) 2001-12-17
PL351148A1 (en) 2003-03-24
NZ515215A (en) 2003-07-25
SK286666B6 (sk) 2009-03-05
EP1180518B1 (en) 2007-01-17
US20060135566A1 (en) 2006-06-22
DK1180518T3 (da) 2007-05-21
HUP0203766A3 (en) 2008-01-28
SI1180518T1 (sl) 2007-06-30
NO20015156L (no) 2001-12-18
PT1180518E (pt) 2007-02-28
MXPA01010675A (es) 2002-06-04
HUP0203766A2 (hu) 2003-03-28
SK14952001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
AP2001002263A0 (en) Process for the manufacture of furfural
AR024800A1 (es) Proceso de produccion de fenil-alcanos
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
NO20015017L (no) Fremgangsmate for fremstilling av citalopram
NO20010318D0 (no) Fremgangsmåte for fremstilling av Citalopram
NO20010319D0 (no) Fremgangsmåte for fremstilling av Citalopram
DE60017012D1 (de) Orginalitätsverschluss und Herstellungverfahren
NO20023549L (no) Fremgangsmåte for rensing av 1,2-dikloretan
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20013880D0 (no) Matriks og fremgangsmate for fremstilling av polyolefin
NO20001909L (no) FremgangsmÕte og anlegg for fremstilling av 1,2-dikloretan
NO20004700D0 (no) FremgangsmÕte for fremstilling av microgeler med kontrollerbar størrelse
NO20031413D0 (no) Ny fremgangsmåte for fremstilling av oksabispidiner
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
NO20000456L (no) FremgangsmÕte for fremstilling av 1,2-dikloretan
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
TR200003585A3 (tr) Vinilaromatik polimerlerin üretimi için islem
NO20022956L (no) Fremgangsmate for fremstilling av nitroguanidin
NO20011652D0 (no) Fremgangsmåte for fremstilling av 1,5-diaryl-3-substituerte pyrazoler
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
FR2797443B1 (fr) Procede de prepartion de quinoleine-5,8-diones
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
AU2795202A (en) Klainetin and derivatives thereof, method for their production and the use of the same

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees